医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020

2021年06月29日 PM08:30
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”). Takeda filed the Annual Report with the SEC on June 29, 2021, and the Annual Report can be accessed on Takeda’s website at: https://www.takeda.com/investors/sec-filings/.

In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at takeda.ir.contact@takeda.com.

Additionally, Takeda also published today its 2021 Annual Integrated Report for the fiscal year ended March 31, 2021. It can be accessed on Takeda’s website at: https://air.takeda.com.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005633/en/

CONTACT

Media:

Japanese Media

Ryoko Matsumoto

ryoko.matsumoto@takeda.com

+81 (0) 3-3278-3414

Media Outside Japan

Christina Beckerman

christina.beckerman@takeda.com

+1 908-581-4133

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Hazelden Betty Ford, Sports Video Group Help Video Production Professionals at the Olympics
  • lululab Leads K-Beauty Advancement With AI-Based Skincare Solution
  • Deargen Signs Agreement With Sookmyung Women’s University Research & Business Development Foundation for Licensing ‘NASH Biomarker’ Technologies
  • Summit Healthcare Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing July 30, 2021
  • ヴィース・センターが脳血管けいれんの新規治療法開発を加速させるべくアーティリア・メディカルと提携